The latest industry information published by Credence Research, Inc. “Global Breast Cancer Treatment industry – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022,” the breast cancer treatment industry was valued at USD 10,682.6 Mn in 2015, and is expected to reach USD 17,345.8 Mn by 2022, expanding at a CAGR of 7.6% from 2016 to 2022.
Breast cancer is typically detected either during a screening examination, before symptoms have developed, or after a woman notices a lump. According to industry experts, breast cancer is the second-largest cause of cancer deaths globally. The rising prevalence of breast cancer across the developed nations has boosted the involvement of non-governmental associations that are spreading awareness related to breast cancer diagnostics and treatment in public. Therapeutic treatment preferred to treat breast cancer involves synthetic to biological drugs.
Browse the full report Breast Cancer Treatment Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report athttp://www.credenceresearch.com/report/breast-cancer-treatment-market
The awareness created around the world in last decade has assisted the industry growth along with industry introduction of premium priced therapies. Moreover, drugs for breast cancer have seen accelerated approvals, thereby providing impetus for breast cancer research and shifting the equilibrium toward research of new effective pathways for intervention of breast cancer. On the other hand, the geographical analysis of breast cancer treatment industry projected North America and Europe as the dominant regions followed by Asia-Pacific. The key factors driving the breast cancer industry in the world include developed research and development facilities, upcoming drug launches, and mounting incidences and awareness of the breast cancer in developing countries. Thus, rising incidences of breast cancer and novel product approvals will lead to significant industry growth during the forecast period, despite generic sales erosion resulting from patent expirations.
The phase III drugs included in the pipeline analysis are Abemaciclib (Eli Lily & Company), Buparlisib (Novartis), NeuVax (Galena Biopharma), Niraparib (Tesaro), Lynparza (AstraZeneca), Veliparib (AbbVie), Neratinib (Puma Biotechnology), Ribociclib (Novartis) and others. According to industry experts, these upcoming drugs assure to provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the currently available breast cancer treatment. Thus, future commercialization of these molecules during the forecast period 2016 – 2022 is anticipated to have a reflective impact on the growth of the overall breast cancer treatment industry.
Request For Free Sample : http://www.credenceresearch.com/sample-request/57921
Key industry Movements:
North America presently dominates the overall industry and is also projected to experience the fastest growth throughout the forecast period
The recent industry entry of novel drugs including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent have boosted the overall growth of breast cancer treatment industry
The companies have been able to develop efficient and commercially successful products by studying pathophysiology of breast cancer in detail, e.g. Herceptin, which is build on the existing scientific groundwork.
Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US